A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy along with Standard Supportive Care in Subjects of mild to moderate Alzheimers disease.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2018
At a glance
- Drugs PMZ 1620 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pharmazz
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 New trial record